<DOC>
	<DOCNO>NCT02414139</DOCNO>
	<brief_summary>A phase II study evaluate antitumor activity oral cMET inhibitor INC280 adult patient EGFR wild-type , advance non-small cell lung cancer ( NSCLC ) measure overall response rate ( ORR ) . The study also evaluate safety pharmacokinetics INC280 .</brief_summary>
	<brief_title>Clinical Study Oral cMET Inhibitor INC280 Adult Patients With EGFR Wild-type Advanced Non-small Cell Lung Cancer</brief_title>
	<detailed_description />
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<criteria>Stage IIIB IV NSCLC ( histology ) time study entry Histologically cytologically confirm diagnosis NSCLC : 1 . EGFR wt per patient standard care validate test 2 . AND ALKnegative rearrangement part patient standard care validate test 3 . AND ( central assessment ) either : Cohort 1 : Pretreated patient cMET GCN ≥ 6 Cohort 2 : Pretreated patient cMET GCN ≥4 &lt; 6 , Cohort 3 : Pretreated patient cMET GCN &lt; 4 , Cohort 4 : Pretreated patient cMET mutation regardless cMET GCN , Cohort 5 : Treatmentnaïve patient cMET dysregulation To eligible Cohorts 14 , patient must fail one two prior line systemic therapy advanced/metastatic disease To eligible Cohort 5 , patient must receive systemic therapy advanced/metastatic disease At least one measurable lesion define RECIST 1.1 Patients must recover toxicity relate prior anticancer therapy grade ≤ 1 ( CTCAE v 4.03 ) . Patients grade alopecia allow enter study . Patients must adequate organ function ECOG performance status ( PS ) 0 1 Details protocoldefined inclusion criterion may apply Prior treatment crizotinib , cMET HGF inhibitor Patients characterize EGFR mutation predict sensitivity EGFR therapy , include , limited exon 19 deletion exon 21 mutation Patients characterize ALKpositive rearrangement Clinically significant , uncontrolled heart disease . Patients receive treatment medication discontinue least 1 week prior first INC280 treatment duration study : Strong moderate inhibitor CYP3A4 Strong inducer CYP3A4 Impairment GI function GI disease may significantly alter absorption INC280 Patients receive treatment enzymeinducing anticonvulsant Applicable Cohorts 14 : Previous anticancer investigational agent within 4 week ≤ 5 x halflife agent ( whichever longer ) first dose Pregnant nursing woman Women childbearing potential , unless use highly effective method contraception Sexually active male unless use condom intercourse Other protocoldefined exclusion criterion may apply</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2017</verification_date>
	<keyword>Non Small Cell Lung</keyword>
	<keyword>cMET</keyword>
</DOC>